Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-06939999 |
| Synonyms | |
| Therapy Description |
PF-06939999 is an inhibitor that blocks PRMT5 methyltransferase activity, resulting in decreased histone H2A, H3, and H4 arginine mono- and di-methylation, which potentially leads to modulation of gene expression resulting in decreased tumor cell growth (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-06939999 | PF06939999|PF 06939999 | PRMT5 Inhibitor 21 | PF-06939999 is an inhibitor that blocks PRMT5 methyltransferase activity, resulting in decreased histone H2A, H3, and H4 arginine mono- and di-methylation, which potentially leads to modulation of gene expression resulting in decreased tumor cell growth (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03854227 | Phase I | PF-06939999 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | Terminated | USA | 0 |